antibiotics

an Open Access Journal by MDPI

IMPACT FACTOR 4.3

Indexed in: PubMed

CITESCORE 7.3

Antimicrobial Use in Pediatrics

Guest Editor:

Dr. Daniele Donà
Division of Pediatric Infectious Diseases, Department of Women's and Children's Health, University of Padova, 35122 Padova, Italy

Deadline for manuscript submissions:
closed (15 August 2022)

Message from the Guest Editor

Antimicrobials are the most commonly prescribed medicine in paediatrics, but between 20 to 50% of these prescriptions have been demonstrated to be potentially unnecessary or inappropriate. This unnecessary exposure increases the risk of severe side effects, raises healthcare costs, and contributes significantly to the global

On the other hand, there is a need to focus on the best dosing strategy for the already available antimicrobials to improve overall outcomes in children and neonates. Understanding pharmacokinetic/pharmacodynamic principles allows the selection of the ideal dosing regimen to eradicate the infection, reduce toxicity, and reduce the development of bacterial resistance.

This process is even more complex in neonates and children. Moreover, further variations in the pharmacokinetics of predominantly hydrophilic antimicrobials occur in critically ill neonates and children.

This Special Issue proposes to explore how to improve the use of antimicrobials in paediatrics, encouraging papers on antimicrobial stewardship programs or strategies to optimise antimicrobial administration and dosing in clinical practice in children and neonates.

antibiotics

IMPACT FACTOR 4.3 | Indexed in: PubMed | CITESCORE 7.3

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
𝕏@antibioticsmdpi